Physician profile
Morgan E Ferruzzi
NPI 1366935728
$564.24
in general payments reported to CMS, 2019-2025
12 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.58 · 2021: $227 · 2024: $118 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96.56 | 2020-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $77.03 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $69.99 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $66.62 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $63.12 | 2021 | |
| Pfizer INC. | $57.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.71 | 2020 | |
| Abbvie INC. | $31.73 | 2021-2025 | |
| Organon LLC | $25.67 | 2024 | |
| Daiichi Sankyo INC. | $15.75 | 2021 | |
| Dexcom, INC. | $15.06 | 2021 | |
| Amgen INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Ferruzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.